Sarepta therapeutics to share expression and safety results from study 103 (endeavor) evaluating srp-9001, its investigational gene therapy for the treatment of duchenne muscular dystrophy

Cambridge, mass., may 17, 2021 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that on tuesday, may 18, 2021 at 8:30 am eastern time, the company will host a webcast and conference call to present 12-week expression and safety results from study srp-9001-103 (study 103), also known as endeavor. study 103 is the first clinical trial using sarepta's commercially representative material for srp-9001 (raavrh74.mhck7.micro-dystrophin) for the treatment of duchenne muscular dystrophy. srp-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
SRPT Ratings Summary
SRPT Quant Ranking